Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy Measures

Silberstein, Stephen D.; Lipton, Richard B.; Dodick, David W.; Freitag, Fred; Mathew, Ninan T.; Brandes, Jan Lewis; Bigal, Marcelo E.; Ascher, Steve; Morein, Jacqueline; Wright, Pamela ‎J.; Greenberg, Steven J.; Hulihan, Joseph

doi:10.1111/j.1526-4610.2009.01508.x

Cited by 116 publications

(83 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Double-blind, placebo-controlled, randomized, and parallel-group studies evaluating patients with chronic migraine who excessively used analgesics showed that topiramate in relatively low doses (50 to 100 mg/day) reduced the frequency of days with pain 71,74 and improved the quality of life of these patients 79 . This action was more efficient after the first four weeks of drug use 79 .…”

Section: Topiramatementioning

confidence: 99%

Latin American consensus on guidelines for chronic migraine treatment

Giacomozzi

Vindas

Silva

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.

show abstract

Section: Topiramatementioning

confidence: 99%

Latin American consensus on guidelines for chronic migraine treatment

Giacomozzi

Vindas

Silva

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…In a large double-blinded placebo-controlled multicenter study, topiramate, while failing to meet its primary endpoints of a decrease in mean monthly total headache days and headache-free days, demonstrated efficacy on several secondary efficacy measures. 71 These included significant reduction of migraine/migrainous days, total headache days, and headache-free days, and improvement in quality of life scores. The mean reduction of monthly headache days was 5.8 for topiramate vs 4.7 days for placebo.…”

Section: Topiramatementioning

confidence: 98%

Chronic Migraine

Cady

Durham

2015

Headache and Migraine Biology and Management

View full text Add to dashboard Cite

“…There are plenty of studies on the effect of therapeutic or prophylactic management of the migraine on HRQOL. In a study in the USA, the effect of treatment with topiramate as the prophylactic treatment of migraine on QOL showed significant improvement of the QOL in the treatment group compared to the control group (13). In another study, the effect of the treatment with propranolol versus behavioral management was assessed; combination of propranolol and behavioral man-agement had positive effect on the QOL (14).…”

Section: Introductionmentioning

confidence: 99%

Quality of Life of Migraine Patients Treated With Combined Propranolol and Topiramate

et al. 2014

View full text Add to dashboard Cite

Background:Migraine is a chronic neurological disorder, which affects the quality of life (QOL). The burden of this disease could be improved by adequate prophylactic treatment. Objectives: We aimed to assess the quality of life in patients with migraine treated with both propranolol and topiramate in Shiraz, Iran. Patients and Methods:In this interventional study, we enrolled 100 newly diagnosed migraine patients who were referred to multidisciplinary clinic of Motahari in Shiraz. Reliable and valid Persian SF-36 questionnaire were used for the evaluation of baseline health-related QOL (HRQOL) and after treatment with 25 mg topiramate (twice daily) and 20 mg propranolol (three times daily) as prophylactic treatment. We used SPSS version 13 for data entry and analysis. Results: Scale differences were statistically significant in all scales before and after the intervention, except in vitality scale. After treatment, the highest score belonged to physical problem and the lowest one was emotional problem. Men had significantly higher scores in body pain compared to women (P = 0.039). Conclusions: Combined migraine prophylaxis with propranolol and topiramate improved HRQOL in migraine sufferers in our study. Adequate prophylaxis improved especially physical problem scale, which manifests with better performing activity and work. More study on the effect of monotherapy along with combined therapy with different doses on HRQOL may be helpful to further evaluate this effect.

show abstract

Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy Measures

Cited by 116 publications

References 37 publications

Latin American consensus on guidelines for chronic migraine treatment

Latin American consensus on guidelines for chronic migraine treatment

Chronic Migraine

Quality of Life of Migraine Patients Treated With Combined Propranolol and Topiramate

Contact Info

Product

Resources

About